Kyorin Pharmaceutical has concluded a basic agreement to transfer its generic pharmaceuticals business to Co-Creation Corporation, a jointly funded entity including Daito Co., Ltd. The succession is scheduled for April 1, 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4569-20260424-01.pdf","jir_short_summary":"Kyorin Pharmaceutical has concluded a basic agreement to transfer its generic pharmaceuticals business to Co-Creation Corporation, a jointly funded entity including Daito Co., Ltd. The succession is scheduled for April 1, 2027.","jir_summary":"### Overview of the Basic Agreement\nKyorin Pharmaceutical Co., Ltd. concluded a basic agreement on April 24, 2026, to transfer the generic pharmaceuticals business and related factories of its consolidated subsidiary, Kyorin Remedio Co., Ltd., to Pharmaceutical Co-Creation Corporation (provisional name), which will be established by joint investors led by Daito Co., Ltd. The business subject to succession excludes the Authorized Generic business and includes the generic pharmaceuticals business and both factories, with the succession planned for April 1, 2027.\n\n### Background of the Business Succession and Future Outlook\nBased on its long-term vision 'Vision 110', the company is focusing management resources on its new pharmaceuticals business, while considering challenges in the generic pharmaceuticals industry such as supply instability and deteriorating profitability. The company decided on this succession to ensure stable supply and establish a sustainable business foundation for the generic pharmaceuticals business. Going forward, maintaining employee employment and labor conditions and stable supply will be the basic policy, and discussions with Daito and others toward concluding final contracts will continue. The impact on consolidated earnings is currently being examined and will be disclosed as necessary.","jir_financial_highlights":"Revenue of the subject company: 34,285 million yen (Fiscal year ending March 2025) (Year-over-Year +8.4% (Up from 31,622 million yen in Fiscal year ending March 2024))\nNet income of the subject company: \u25b3519 million yen (Fiscal year ending March 2025) (Turned to deficit (Deficit widened from \u25b3398 million yen in Fiscal year ending March 2024))\nNumber of employees at the subject factories: 206 persons (Takaoka Factory 37 persons, Inami Factory 169 persons, as of March 2025) (Unknown)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #M&A, #GenericPharmaceuticalsBusiness","jir_key_figures":"Revenue of the subject company: 34,285 million yen (Fiscal year ending March 2025)\nNet income of the subject company: \u25b3519 million yen (Fiscal year ending March 2025)\nPlanned execution date of the succession: 2027-04-01","jir_meta_title":"[Kyorin Pharmaceutical] Succession of Generic Pharmaceuticals Business to Co-Creation Corporation | April 2026","jir_meta_description":"Kyorin Pharmaceutical has concluded a basic agreement to transfer its generic pharmaceuticals business to a new company jointly funded by Daito Co., Ltd. and others. The succession is scheduled for April 2027, aiming to strengthen stable supply systems.","jir_og_title":"[Kyorin Pharmaceutical] Succession of Generic Pharmaceuticals Business to Co-Creation Corporation | April 2026","jir_og_description":"Kyorin Pharmaceutical announced a basic agreement to transfer the generic pharmaceuticals business to a jointly funded company. The succession is scheduled for April 2027, aiming to ensure stable supply.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-42385","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n